Asembia AXS26: How CGTs Are Reshaping Specialty Pharmacy

Key Takeaways

• CGTs replace buy‑and‑bill with patient‑specific, coordinated workflows
• Specialized steps include apheresis, conditioning, and cold‑chain handling
• Upfront therapy costs pressure the entire distribution network
• Specialty pharmacies now may assume financial risk to enable access

Pulse Analysis

Cell and gene therapies are accelerating faster than the infrastructure built to deliver them. Unlike conventional biologics, CGTs often require a one‑time infusion, precise dosing, and pre‑treatment procedures such as apheresis or conditioning regimens. This clinical complexity forces specialty pharmacies to integrate tightly with treatment centers, manage cold‑chain storage, and orchestrate real‑time logistics, reshaping the traditional distribution paradigm.

Operationally, the shift introduces new layers of coordination. Pharmacies must track patient eligibility, schedule complex procedures, and ensure temperature‑controlled transport from manufacturing sites to infusion centers. The need for real‑time data exchange between clinicians, payers, and logistics providers heightens the importance of digital platforms that can handle end‑to‑end visibility. As a result, firms that invest in robust supply‑chain technology and clinical support services gain a competitive edge in the emerging CGT market.

Financially, the massive upfront price tags of CGTs—often exceeding several hundred thousand dollars—have spurred innovative payment models. Specialty pharmacies are increasingly entering risk‑sharing agreements, acting as intermediaries that assume part of the cost to secure patient access. These arrangements can include outcomes‑based contracts or installment payments, shifting some financial burden from insurers to the pharmacy network. By shouldering risk, pharmacies not only facilitate therapy adoption but also position themselves as strategic partners in value‑based care, a trend likely to expand as more CGTs receive regulatory approval.